Yuanyuan Ling

1.2k total citations · 1 hit paper
10 papers, 872 citations indexed

About

Yuanyuan Ling is a scholar working on Molecular Biology, Oncology and Rheumatology. According to data from OpenAlex, Yuanyuan Ling has authored 10 papers receiving a total of 872 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Rheumatology. Recurrent topics in Yuanyuan Ling's work include Cytokine Signaling Pathways and Interactions (3 papers), Rheumatoid Arthritis Research and Therapies (2 papers) and Advancements in Transdermal Drug Delivery (1 paper). Yuanyuan Ling is often cited by papers focused on Cytokine Signaling Pathways and Interactions (3 papers), Rheumatoid Arthritis Research and Therapies (2 papers) and Advancements in Transdermal Drug Delivery (1 paper). Yuanyuan Ling collaborates with scholars based in China and United States. Yuanyuan Ling's co-authors include Laura J. Niedernhofer, Paul D. Robbins, Heike Fuhrmann‐Stroissnigg, Cory B. Giles, James L. Kirkland, Tamar Tchkonia, Tamar Pirtskhalava, Kurt O. Johnson, Jonathan D. Wren and Yi Zhu and has published in prestigious journals such as International Journal of Pharmaceutics, Molecular Pharmacology and Medicine.

In The Last Decade

Yuanyuan Ling

10 papers receiving 858 citations

Hit Papers

Identification of a novel senolytic agent, navitoclax, ta... 2015 2026 2018 2022 2015 250 500 750

Peers

Yuanyuan Ling
Yuanyuan Ling
Citations per year, relative to Yuanyuan Ling Yuanyuan Ling (= 1×) peers Ronit Tokarsky-Amiel

Countries citing papers authored by Yuanyuan Ling

Since Specialization
Citations

This map shows the geographic impact of Yuanyuan Ling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanyuan Ling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanyuan Ling more than expected).

Fields of papers citing papers by Yuanyuan Ling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuanyuan Ling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanyuan Ling. The network helps show where Yuanyuan Ling may publish in the future.

Co-authorship network of co-authors of Yuanyuan Ling

This figure shows the co-authorship network connecting the top 25 collaborators of Yuanyuan Ling. A scholar is included among the top collaborators of Yuanyuan Ling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanyuan Ling. Yuanyuan Ling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Li, Xiaoqian, Yuanyuan Ling, Mei Wang, et al.. (2024). Association between mitophagy and NLRP3 inflammasome in uric acid nephropathy. Renal Failure. 46(2). 2438847–2438847. 3 indexed citations
2.
Ling, Yuanyuan, et al.. (2023). Clinical characteristics, early blood biochemical indicators, and prognostic status of children with bronchopneumonia. Medicine. 102(47). e36162–e36162. 2 indexed citations
3.
Ling, Yuanyuan, Jie Yang, Di Hua, et al.. (2021). ZhiJingSan Inhibits Osteoclastogenesis via Regulating RANKL/NF-κB Signaling Pathway and Ameliorates Bone Erosion in Collagen-Induced Mouse Arthritis. Frontiers in Pharmacology. 12. 693777–693777. 10 indexed citations
4.
Hua, Di, Jie Yang, Qinghai Meng, et al.. (2021). Soufeng sanjie formula alleviates collagen-induced arthritis in mice by inhibiting Th17 cell differentiation. Chinese Medicine. 16(1). 39–39. 16 indexed citations
5.
Zhu, Jinchang, Song Ye, Juan Ye, et al.. (2020). Prolonged melittin release from polyelectrolyte-based nanocomplexes decreases acute toxicity and improves blood glycemic control in a mouse model of type II diabetes. International Journal of Pharmaceutics. 577. 119071–119071. 14 indexed citations
6.
Handel, Ben Van, et al.. (2019). Targeted small molecule-mediated immunomodulation of GP130 receptor attenuates rheumatoid arthritis in rats. Osteoarthritis and Cartilage. 27. S381–S382. 2 indexed citations
7.
Fuhrmann‐Stroissnigg, Heike, Fernando E. Santiago, Diego Grassi, et al.. (2019). SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs. Journal of Visualized Experiments. 1 indexed citations
8.
Lafitte, M., Víctor Quereda, Daniel Feurstein, et al.. (2015). Identification of an EGFRvIII-JNK2-HGF/c-Met–Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion. Molecular Pharmacology. 88(6). 962–969. 15 indexed citations
9.
Zhu, Yi, Tamar Tchkonia, Heike Fuhrmann‐Stroissnigg, et al.. (2015). Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors. Aging Cell. 15(3). 428–435. 803 indexed citations breakdown →
10.
Ling, Yuanyuan, et al.. (2010). CEO golden‐mean thinking, ambidextrous orientation and organizational performance in Chinese context. Nankai Business Review International. 1(4). 460–479. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026